Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Por Petrylak, Daniel P
Publicado em 2003

Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Por Petrylak, Daniel P
Publicado em 2003

The Treatment of Hormone-Refractory Prostate Cancer: Docetaxel and Beyond

Por Petrylak, Daniel P
Publicado em 2006

New Paradigms for Advanced Prostate Cancer

Por Petrylak, Daniel P
Publicado em 2007

New developments in the treatment of castration resistant prostate cancer

Por Wadia, Roxanne, Petrylak, Daniel P
Publicado em 2014

Prostate Cancer Update: Advanced Disease

Por Carducci, Michael A, Crawford, E. David, Higano, Celestia S, Mendoza-Valdes, Arturo, Petrylak, Daniel P, Schalken, Jack
Publicado em 2003

Hormone-Refractory Prostate Cancer: New Horizons

Por Petrylak, Daniel P, Abrahamsson, Per-Anders, Bartsch, Georg, Carducci, Michael A, Small, Eric J, Wilding, George
Publicado em 2003

Androgen Deprivation and Other Treatments for Advanced Prostate Cancer

Por Brawer, Michael K, Crawford, E David, Labrie, Fernand, Mendoza-Valdes, Arturo, Miller, Paul D, Petrylak, Daniel P
Publicado em 2001

Therapeutic Strategies for Localized Prostate Cancer

Por Lynch, John H, Batuello, Joseph T, Crawford, E David, Gomella, Leonard G, Kaufman, Joel, Petrylak, Daniel P, Joel, Andrew B
Publicado em 2001

Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

Por Armstrong, Andrew J., Eisenberger, Mario A., Halabi, Susan, Oudard, Stephane, Nanus, David M., Petrylak, Daniel P., Sartor, A. Oliver, Scher, Howard I.
Publicado em 2011

GEMCITABINE AND CISPLATIN IN UNRESECTABLE MALIGNANT MESOTHELIOMA OF THE PLEURA: A PHASE II STUDY OF THE SOUTHWEST ONCOLOGY GROUP (SWOG 9810)

Por Kalmadi, Sujith R., Rankin, Cathryn, Kraut, Michael J., Jacobs, Andrew D., Petrylak, Daniel P., Adelstein, David J., Keohan, Mary Louise, Taub, Robert N., Borden, Ernest C.
Publicado em 2007

A Double Blind Randomized Crossover Study of Oral Thalidomide versus Placebo in Patients with Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation

Por Figg, William D., Hussain, Maha H., Gulley, James L., Arlen, Philip M., Aragon-Ching, Jeanny B., Petrylak, Daniel P., Higano, Celestia S., Steinberg, Seth M., Sartor, Oliver, Dahut, William L.
Publicado em 2009

Cooperative group trials – Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Por Dorff, Tanya B., Tangen, Cathy M., Crawford, E. David, Petrylak, Daniel P., Higano, Celestia S., Raghavan, Derek, Quinn, David I., Vogelzang, Nicholas J., Thompson, Ian M., Hussain, Maha H.A.
Publicado em 2009

SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Gué...

Por Skinner, Eila C., Goldman, Bryan, Sakr, Wael A., Petrylak, Daniel P., Lenz, Heinz-Josef, Lee, Cheryl T., Wilson, Shandra S., Benson, Mitchell, Lerner, Seth P., Tangen, Cathy M., Thompson, Ian M.
Publicado em 2013

Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients with Locally Advanced Carcinoma of the Bladder

Por Smith, David C., Mackler, Niklas J, Dunn, Rodney L., Hussain, Maha, Wood, David, Lee, Cheryl T., Sanda, Martin, Vaishampayan, Ulka, Petrylak, Daniel P., Quinn, David I., Beekman, Kathleen, Montie, James E.
Publicado em 2008

KINETICS OF SERUM ANDROGEN NORMALIZATION AND FACTORS ASSOCIATED WITH TESTOSTERONE RESERVE AFTER LIMITED ANDROGEN-DEPRIVATION THERAPY IN NONMETASTATIC PROSTATE CANCER

Por Gulley, James L., Aragon-Ching, Jeanny B., Steinberg, Seth M., Hussain, Maha H., Sartor, Oliver, Higano, Celestia S., Petrylak, Daniel P., Chatta, Gurkamal S., Arlen, Philip M., Figg, William D., Dahut, William L.
Publicado em 2008

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer

Por Petrylak, Daniel P., Gandhi, Jitendra G., Clark, William R., Heath, Elisabeth, Lin, Jianqing, Oh, William K., Agus, David B., Carthon, Bradley, Moran, Susan, Kong, Ning, Suri, Ajit, Bargfrede, Michael, Liu, Glenn
Publicado no Invest New Drugs (2015)

Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162)...

Por Hussain, Maha, Goldman, Bryan, Tangen, Cathy, Higano, Celestia S., Petrylak, Daniel P., Wilding, George, Akdas, Atif M., Small, Eric J., Donnelly, Bryan J., Sundram, Subramanian Kanaga, Burch, Patrick A., DiPaola, Robert S., Crawford, E. David
Publicado em 2009

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

Por Xiao, Yuanyuan, Rabe, Christina, Kowanetz, Marcin, Powles, Thomas, Vogelzang, Nicholas J, Petrylak, Daniel P, Loriot, Yohann, Denker, Mitchell, Nakamura, Rin, Wu, Qun J, Sumiyoshi, Teiko, Boyd, Zachary, Teng, Siew-leng M, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Publicado no J Immunother Cancer (2014)

Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer

Por Motamedinia, Piruz, Scott, Anna N., Bate, Kendall L., Sadeghi, Neda, Salazar, Guillermo, Shapiro, Edan, Ahn, Jennifer, Lipsky, Michael, Lin, James, Hruby, Greg W., Badani, Ketan K., Petrylak, Daniel P., Benson, Mitchell C., Donovan, Michael J., Comper, Wayne D., McKiernan, James M., Russo, Leileata M.
Publicado no PLoS One (2016)